SA
SCPH

Sanctuary Advisors’s scPharmaceuticals SCPH Stock Holding History

Sanctuary Advisors’s Portfolio SCPH Stock Details SCPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-16,555
Closed -$55.5K – 2484
2024
Q3 		$55.5K Buy
+16,555
New +$80.1K ﹤0.01% 2340

Other funds holding SCPH

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Luther King Capital Management (LKCM)
Luther King Capital Management (LKCM) Fort Worth, Texas $24.4B AUM 22.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.87B AUM 46.92% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

Sanctuary Advisors's SCPH Position: Q4 2024 in Review

Sanctuary Advisors sold out of scPharmaceuticals (SCPH) in Q4 2024, closing a stake of 16,555 shares — an estimated $55.5K sold.

Sanctuary Advisors first reported a position in SCPH in Q3 2024 and held it in 1 quarter. The position peaked at $55.5K in Q3 2024. 85 funds tracked by Wall St. Rank hold SCPH as of Q4 2024.

  • Sanctuary Advisors reported no remaining scPharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Sanctuary Advisors sold 16,555 scPharmaceuticals shares in Q4 2024, an estimated $55.5K.
  • Sanctuary Advisors first reported a position in scPharmaceuticals in Q3 2024 and held it in 1 quarter.
  • Sanctuary Advisors's scPharmaceuticals position peaked at $55.5K in Q3 2024.
  • 85 funds tracked by Wall St. Rank held scPharmaceuticals as of Q4 2024.

Based on Sanctuary Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.